New COVID-19 Vaccine

by | Jun 16, 2021 | COVID-19, Healthcare, Pharmaceuticals, Quality, Vaccine

Starting in Summer 2021, a new type of COVID vaccine could be available. Known as a protein subunit vaccine, this vaccine contains a spike protein that the other three vaccines are missing. The other vaccines, Pfizer, Moderna, and Johnson & Johnson, contain instructions for the spike protein but do not actually include the spike protein in the vaccination. The three vaccines allow our cell bodies to make the protein up for itself.

Vaccines normally work by showing a resemblance of a virus but are not. After the vaccine is administered and the real virus shows up, the immune system is ready to fight and conquer the virus. In a protein subunit vaccine, the resemblance in the vaccine is actually one of the proteins in the virus: the spike protein.

Protein subunit vaccines have been around for a long time. Vaccines for hepatitis B and pertussis, or known as whooping cough, are based on this technology. This technology works a bit differently from other vaccines that are authorized in the United States by containing the spike protein along with an adjuvant that improves the immune responses to make the vaccine more proactive and protective.

This protein subunit vaccine will come from a biotech company called Novavax. Novavax utilizes a giant vat of cells that were artificially grown in the lab. To test the effectiveness of this new vaccine, Doctor Gregory Glenn, the president of research and development at Novavax, conducted a study with over ten thousand volunteers throughout the United States and Mexico. He mentioned that Novavax anticipates filing for FDA authorization in the United Kingdom, United States, and Europe before the third quarter.

To learn more about quality, regulatory, or compliance, EMMA International’s team of experts has you covered. Contact us at 248-987-4497, or email info@emmainternational.com today!

 

1A New Type Of COVID-19 Vaccine Could Debut Soon. (2021, June 6). NPR.org. https://www.npr.org/sections/health-shots/2021/06/06/1003328413/new-type-of-covid-vaccine-could-debut-soon

Abby McVay

Abby McVay

Research Analyst- Ms. McVay is EMMA International’s Research Analyst. She has experience in technical writing and clinical trials in many life science industries. She has experience with many different elements of quality and regulatory compliance. Ms. McVay holds a Bachelor of Science in Psychology from Manchester University as well as a Master of Science in Industrial and Organizational Psychology from Angelo State University.

More Resources

FDA Adverse Event Reporting 

FDA Adverse Event Reporting 

When reporting an Adverse Event to the Food and Drug Administration (FDA) the best method is to utilize the FDA Adverse Event Reporting System (FAERS). FAERS is a database that contains adverse event reports, product quality complaints that led to an adverse event, and medication error reports1. All FAERS reports are easily accessible to the public. 
De Novo Classification

De Novo Classification

A device can be registered for the De Novo pathway if there is evidence of the safety and effectiveness of the device and there is not a previously legally marketed predicate device1. When determining if your device can go through the De Novo process there are two pathways available to determine the device classification.
Abbreviated 510k submission

Abbreviated 510k submission

There are three types of 510K, Premarket Notifications, which can be submitted to the Food and Drug Administration (FDA) traditional, abbreviated, and special. Abbreviated and Special 510K submissions can be utilized when the submissions meet the certain factors presented by the FDA. When submitting an abbreviated 510K the submission must include the elements that are identified in 21CFR 807.87 for the information required in a premarket notification submission.

Ready to learn more about working with us?

Pin It on Pinterest

Share This